Literature DB >> 16646031

Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome.

Thomas Egerer1, Lorena Martinez-Gamboa, Anja Dankof, Bruno Stuhlmüller, Thomas Dörner, Veit Krenn, Karl Egerer, Paul E Rudolph, Gerd-R Burmester, Eugen Feist.   

Abstract

OBJECTIVE: Sjögren's syndrome (SS) is characterized by autoimmune infiltration and focal accumulation of lymphocytes in the exocrine glands, with a predominance of CD4-positive T cells. Since these histologic findings are nonspecific, determination of clinical and serologic abnormalities contribute to the diagnosis. The aim of this study was to identify a novel, disease-specific, immunologically relevant marker for SS.
METHODS: To analyze disease-related and tissue-specific expression of candidate markers, we examined biopsied minor salivary glands and peripheral blood mononuclear cells from patients with primary and secondary SS (n = 26) as well as from patients with sicca symptoms without autoimmune sialadenitis (n = 15). Expression of the Th1/Th2-related chemokines CCL3 (macrophage inflammatory protein 1alpha) and CCL2 (monocyte chemoattractant protein 1), CXCL7 (neutrophil-activating peptide 2 [NAP-2]), interleukin-1beta, inducible costimulator, and the proteasome subunits alpha3 (C9) and beta5i (LMP7) was analyzed at the messenger RNA (mRNA) level using real-time polymerase chain reaction techniques. Immunohistochemical analysis was used to identify the beta5i (LMP7)-expressing cell populations in minor salivary glands.
RESULTS: The expression profiles revealed a significant up-regulation of beta5i (LMP7) exclusively in the salivary glands of SS patients. Immunohistochemistry confirmed expression of the immunoproteasome subunit beta5i (LMP7) within the acinar and ductal epithelial cells. No significant difference in the distinct histologic focus scores was evident for the expression of the markers investigated. In the peripheral blood compartment, the expression of CXCL7 was up-regulated both in primary and in secondary SS.
CONCLUSION: Tissue-specific up-regulation of beta5i (LMP7) mRNA was shown to be characteristic of SS, indicating a disease-specific modulation of the proteasome system. Expression of beta5i (LMP7) represents an independent parameter that can be used in addition to the focus score to distinguish SS in biopsied labial salivary glands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16646031     DOI: 10.1002/art.21782

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

1.  Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.

Authors:  André S Bachmann; John Opoku-Ansah; Tannya R Ibarra-Rivera; Lisette P Yco; Sudhakar Ambadi; Christopher C Roberts; Chia-En A Chang; Michael C Pirrung
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

2.  Salivary chemokine levels in patients with primary Sjogren's syndrome.

Authors:  Yun Jong Lee; Robert H Scofield; Joon Young Hyon; Pil-Young Yun; Hyo-Jung Lee; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Rheumatology (Oxford)       Date:  2010-06-04       Impact factor: 7.580

Review 3.  Emerging roles of immunoproteasomes beyond MHC class I antigen processing.

Authors:  Frédéric Ebstein; Peter-Michael Kloetzel; Elke Krüger; Ulrike Seifert
Journal:  Cell Mol Life Sci       Date:  2012-03-02       Impact factor: 9.261

4.  Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjögren's syndrome.

Authors:  Fan Xiao; Xiang Lin; Jie Tian; Xiaohui Wang; Qian Chen; Ke Rui; Jie Ma; Shengjun Wang; Qingwen Wang; Xiaoqi Wang; Dongzhou Liu; Lingyun Sun; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2017-07-10       Impact factor: 11.530

5.  Proteomic identification of immunoproteasome accumulation in formalin-fixed rodent spinal cords with experimental autoimmune encephalomyelitis.

Authors:  Mohit Raja Jain; Qing Li; Tong Liu; Joseph Rinaggio; Amit Ketkar; Vincent Tournier; Kiran Madura; Stella Elkabes; Hong Li
Journal:  J Proteome Res       Date:  2012-02-06       Impact factor: 4.466

Review 6.  [Is bioptic assurance reasonable in patients with Sjögren's syndrome? From focus score to diagnosing vasculitides].

Authors:  V Krenn; M Jakobs; J Kriegsmann; M G Krukemeyer; A Rieger
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

7.  [Labial salivary gland biopsy in Sjögren's syndrome].

Authors:  A Dankof; L Morawietz; E Feist
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

Review 8.  Mechanisms of isolevuglandin-protein adduct formation in inflammation and hypertension.

Authors:  Liang Xiao; David M Patrick; Luul A Aden; Annet Kirabo
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-09-29       Impact factor: 3.072

9.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

10.  Immunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: studies in humans and mice.

Authors:  Hiroaki J Kimura; Cindy Y Chen; Shey-Cherng Tzou; Roberto Rocchi; Melissa A Landek-Salgado; Koichi Suzuki; Miho Kimura; Noel R Rose; Patrizio Caturegli
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.